Serum Adiponectin Level in Different Stages of Type 2 Diabetic Kidney Disease: A Meta-Analysis.

Published
July 26, 2022
Journal
Computational and mathematical methods in medicine
PICOID
a67fbb38
DOI
Citations
1
Keywords
Copyright
Copyright © 2022 Li Li et al.
Patients/Population/Participants

type 2 diabetes mellitus patients

Intervention

adiponectin

Comparison

normoalbuminuria and control group

Outcome

severity of type 2 diabetic kidney disease

Abstract

P
I
C
O

Biomarkers in predicting the stages of nephropathy associated with type 2 diabetes mellitus are urgent, and adiponectin may be a promising biomarker. This meta-analysis examined the association of serum adiponectin level with the stages of type 2 diabetic nephropathy. Databases including PubMed, Cochrane Library, EMBASE, China National Knowledge Infrastructure (CNKI), and Wan Fang were searched for published studies on adiponectin and type 2 diabetic kidney disease. The Newcastle-Ottawa scale was used to assess the quality of the literature. STATA 14.0 was used to conduct the statistical analysis. Thirty-four studies with 5254 patients were included in this meta-analysis. The results of this study show that there was no significant difference in serum adiponectin level between normoalbuminuria and the control group (mean difference = -0.42, 95% CI [-1.23, 0.40]), while serum adiponectin level was positively correlated with the severity of type 2 diabetic kidney disease. The serum adiponectin level in type 2 diabetic kidney disease patients ranks as macroalbuminuria > microalbuminuria > normoalbuminuria. Serum adiponectin level might be an important marker to predict the progression of type 2 diabetic kidney disease.

Similar article map

CEO: Hwi-yeol YunCOO: Jung-woo ChaeCTO: Sangkeun Jung
Location: 204, W6, Chungnam National University, 99, Daehak-ro, Yuseong-gu, Daejeon, Republic of Korea
Tel: 042-821-7328E-mail: webmaster@lilac-co.kr
Copyright © 2024 by LiLac. All Rights Reserved.